Table 2.
Baseline Characteristics of Patients With CD4 Cells. CD8 Cells and HI Viral Load at Baseline, Overall and for Patients With Incident Cancers
| PWH Included in the Analysis |
PWH With Non-AIDS Defining Malignancy |
PWH With AIDS Defining Malignancy |
PWH With Infection-Related Malignancy |
PWH With Smoking-Related Malignancy |
PWH With Body Mass Index-Related Malignancy |
|
|---|---|---|---|---|---|---|
| (n = 19 247) | (n = 610) | (n = 139) | (n = 258) | (n = 284) | (n = 145) | |
| Age [y] | ||||||
| <50 | 13 698 (71.2%) | 229 (37.5%) | 84 (60.4%%) | 139 (53.9%%) | 98 (34.5%%) | 61 (42.1%%) |
| 50–65 | 4746 (24.7%) | 302 (49.5%%) | 46 (33.1%%) | 100 (38.8%%) | 151 (53.2%) | 70 (48.3%) |
| ≥65 | 803 (4.2%) | 79 (13.0%) | 9 (6.5%) | 19 (7.4%) | 35 (12.3%) | 14 (9.7%) |
| Median age (interquartile range) [y] | 44 (36–51) | 52 (47–59) | 46 (38–52) | 49 (42–55) | 52 (47–59) | 51 (46–57) |
| Sex | ||||||
| Male | 14 715 (76.5%) | 484 (79.3%) | 108 (77.7%) | 213 (82.6%) | 223 (78.5%) | 110 (75.9%) |
| Female | 4532 (23.5%) | 126 (20.7%) | 31 (22.3%) | 45 (17.4%) | 61 (21.5%) | 35 (24.1%) |
| Risk group | ||||||
| Men having sex with men | 9596 (49.9%) | 267 (43.8%) | 75 (54.0%) | 134 (51.9%) | 100 (35.2%) | 51 (35.2%) |
| People who inject drugs | 1921 (10.0%) | 111 (18.2%) | 14 (10.1%) | 31 (12.0%) | 76 (26.8%) | 33 (22.8%) |
| Heterosexual | 6544 (34.0%) | 195 (32.0%) | 39 (28.1%) | 74 (28.7%) | 91 (32.0%) | 52 (35.9%) |
| Other/unknown | 1186 (6.2%) | 37 (6.1%) | 11 (7.9%) | 19 (7.4%) | 17 (6.0%) | 9 (6.2%) |
| Race | ||||||
| White | 12 934 (67.2%) | 477 (78.2%) | 92 (66.2%) | 181 (70.2%) | 233 (82.0%) | 107 (73.8%) |
| Other/unknown | 6313 (32.8%) | 133 (21.8%) | 47 (33.8%) | 77 (29.8%) | 51 (18.0%) | 38 (26.2%) |
| CD4 cell count [cells/μL] | ||||||
| <350 | 4731 (24.6%) | 165 (27.0%) | 56 (40.3%) | 95 (36.8%) | 78 (27.5%) | 36 (24.8%) |
| 350–500 | 4233 (22.0%) | 127 (20.8%) | 34 (24.5%) | 59 (22.9%) | 58 (20.4%) | 33 (22.8%) |
| ≥500 | 10 283 (53.4%) | 318 (52.1%) | 49 (35.3%) | 104 (40.3%) | 148 (52.1%) | 76 (52.4%) |
| CD8 cell count [cells/μL] | ||||||
| <1000 | 12 533 (65.1%) | 386 (63.3%) | 77 (55.4%) | 148 (57.4%) | 181 (63.7%) | 91 (62.8%) |
| ≥1000 | 6714 (34.9%) | 224 (36.7%) | 62 (44.6%) | 110 (42.6%) | 103 (36.3%) | 54 (37.2%) |
| CD4:CD8 ratio | ||||||
| <0.5 | 7271 (37.8%) | 238 (39.0%) | 80 (57.6%) | 140 (54.3%) | 114 (40.1%) | 57 (39.3%) |
| 0.5–1.0 | 8119 (42.2%) | 247 (40.5%) | 42 (30.2%) | 83 (32.2%) | 115 (40.5%) | 57 (39.3%) |
| ≥1 | 3857 (20.0%) | 125 (20.5%) | 17 (12.2%) | 35 (13.6%) | 55 (19.4%) | 31 (21.4%) |
| HI viral load [copies/mL] | ||||||
| <200* | 12 590 (65.4%) | 485 (79.5%) | 75 (54.0%) | 167 (64.7%) | 233 (82.0%) | 119 (82.1%) |
| ≥200 | 6657 (34.6%) | 125 (20.5%) | 64 (46.0%) | 91 (35.3%) | 51 (18.0%) | 26 (17.9%) |
| Body mass index [kg/m2] | ||||||
| <30 | 12 785 (66.4%) | 435 (71.3%) | 81 (58.3%) | 168 (65.1%) | 214 (75.4%) | 110 (75.9%) |
| ≥30 | 1128 (5.9%) | 40 (6.6%) | 6 (4.3%) | 17 (6.6%) | 19 (6.7%) | 14 (9.7%) |
| Missing | 5334 (27.7%) | 135 (22.1%) | 52 (37.4%) | 73 (28.3%) | 51 (18.0%) | 21 (14.5%) |
| Hepatitis C status | ||||||
| Negative | 14 029 (72.9%) | 406 (66.6%) | 94 (67.6%) | 169 (65.5%) | 170 (59.9%) | 93 (64.1%) |
| Positive | 2981 (15.5%) | 152 (24.9%) | 19 (13.7%) | 50 (19.4%) | 95 (33.5%) | 45 (31.0%) |
| Unknown | 2237 (11.6%) | 52 (8.5%) | 26 (18.7%) | 39 (15.1%) | 19 (6.7%) | 7 (4.8%) |
| Hepatitis B status | ||||||
| Negative | 16 029 (83.3%) | 532 (87.2%) | 106 (76.3%) | 203 (78.7%) | 255 (89.8%) | 131 (90.3%) |
| Positive | 735 (3.8%) | 29 (4.8%) | 7 (5.0%) | 18 (7.0%) | 15 (5.3%) | 8 (5.5%) |
| Unknown | 2483 (12.9%) | 49 (8.0%) | 26 (18.7%) | 37 (14.3%) | 14 (4.9%) | 6 (4.1%) |
| Smoking | ||||||
| No | 7043 (36.6%) | 236 (38.7%) | 50 (36.0%) | 95 (36.8%) | 89 (31.3%) | 67 (46.2%) |
| Yes | 6018 (31.3%) | 225 (36.9%) | 32 (23.0%) | 73 (28.3%) | 128 (45.1%) | 48 (33.1%) |
| Unknown | 6186 (32.1%) | 149 (24.4%) | 57 (41.0%) | 90 (34.9%) | 67 (23.6%) | 30 (20.7%) |
| Median time on ART at diagnosis | ||||||
| (interquartile range) [y] | … | 13.7 (7.8–19.3) | 9.1 (4.3–16.4) | 12.3 (5.8–18.4) | 15.0 (8.8–19.0) | 14.9 (9.1–19.0) |
Positive hepatitis C is defined as detectable RNA or a positive immunoglobulin G (IgG) antibody test; positive hepatitis B is defined as surface antigen positivity.
Abbreviations: ART, antiretroviral therapy; PWH, people with human immunodeficiency virus (HIV).